B Alex Matthews1, John S Rhee, Marcy Neuburg, Mary L Burzynski, Ann B Nattinger. 1. Health Policy Institute, Center for Patient Care & Outcomes Research, Department of Otolaryngology and Communication Sciences, Froedtert Memorial Lutheran Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin 53226-0509, USA. amatthew@mcw.edu
Abstract
BACKGROUND: Existing health-related quality-of-life (HRQOL) tools do not appear to capture patients' specific skin cancer concerns. OBJECTIVE: To describe the conceptual foundation, item generation, reduction process, and reliability testing for the Facial Skin Cancer Index (FSCI), a HRQOL outcomes tool for skin cancer researchers and clinicians. METHODS: Participants in Phases I to III consisted of adult patients (N=134) diagnosed with biopsy-proven nonmelanoma cervicofacial skin cancer. Data were collected via self-report surveys and clinical records. RESULTS: Seventy-one distinct items were generated in Phase I and rated for their importance by an independent sample during Phase II; 36 items representing six theoretical HRQOL domains were retained. Test-retest I results indicated that four subscales showed adequate reliability coefficients (alpha=0.60 to 0.91). Twenty-six items remained for test-retest II. Results indicated excellent internal consistency for emotional, social, appearance, and modified financial/work subscales (range 0.79 to 0.95); test-retest correlation coefficients were consistent across time (range 0.81 to 0.97; lifestyle omitted). CONCLUSION: Pretesting afforded the opportunity to select items that optimally met our a priori conceptual and psychometric criteria for high data quality. Phase IV testing (validity and sensitivity before surgery and 4 months after Mohs micrographic surgery) for the 20-item FSCI is under way.
BACKGROUND: Existing health-related quality-of-life (HRQOL) tools do not appear to capture patients' specific skin cancer concerns. OBJECTIVE: To describe the conceptual foundation, item generation, reduction process, and reliability testing for the Facial Skin Cancer Index (FSCI), a HRQOL outcomes tool for skin cancer researchers and clinicians. METHODS:Participants in Phases I to III consisted of adult patients (N=134) diagnosed with biopsy-proven nonmelanoma cervicofacial skin cancer. Data were collected via self-report surveys and clinical records. RESULTS: Seventy-one distinct items were generated in Phase I and rated for their importance by an independent sample during Phase II; 36 items representing six theoretical HRQOL domains were retained. Test-retest I results indicated that four subscales showed adequate reliability coefficients (alpha=0.60 to 0.91). Twenty-six items remained for test-retest II. Results indicated excellent internal consistency for emotional, social, appearance, and modified financial/work subscales (range 0.79 to 0.95); test-retest correlation coefficients were consistent across time (range 0.81 to 0.97; lifestyle omitted). CONCLUSION: Pretesting afforded the opportunity to select items that optimally met our a priori conceptual and psychometric criteria for high data quality. Phase IV testing (validity and sensitivity before surgery and 4 months after Mohs micrographic surgery) for the 20-item FSCI is under way.
Authors: B Alex Matthews; Frank Baker; Danette M Hann; Maxine Denniston; Tenbroeck G Smith Journal: Psychooncology Date: 2002 May-Jun Impact factor: 3.894
Authors: John S Rhee; B Alex Matthews; Marcy Neuburg; Timothy L Smith; Mary Burzynski; Ann B Nattinger Journal: Arch Otolaryngol Head Neck Surg Date: 2004-02
Authors: John S Rhee; Fausto R Loberiza; B Alex Matthews; Marcy Neuburg; Timothy L Smith; Mary Burzynski Journal: Laryngoscope Date: 2003-02 Impact factor: 3.325
Authors: John S Rhee; B Alex Matthews; Marcy Neuburg; Brent R Logan; Mary Burzynski; Ann B Nattinger Journal: Arch Facial Plast Surg Date: 2006 Sep-Oct
Authors: John S Rhee; B Alex Matthews; Marcy Neuburg; Brent R Logan; Mary Burzynski; Ann B Nattinger Journal: Laryngoscope Date: 2007-03 Impact factor: 3.325
Authors: Sara Falivene; Francesca Maria Giugliano; Antonio Maria Grimaldi; Rossella Di Franco; Diego Toledo; Matteo Muto; Fabrizio Cammarota; Valentina Borzillo; Paolo Antonio Ascierto; Paolo Muto Journal: BMC Dermatol Date: 2014-09-30
Authors: M de Troya-Martín; F Rivas-Ruiz; N Blázquez-Sánchez; I Fernández-Canedo; M Aguilar-Bernier; J B Repiso-Jiménez; J C Toribio-Montero; M Jones-Caballero; J Rhee Journal: J Skin Cancer Date: 2016-10-09